Lensar (LNSR) Free Cash Flow Growth (1y) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -1.82% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 226.77% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 9.73% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -51.69% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -109.40% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 133.09% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 363.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 108.16% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 29.12% |
| 10 | Lensar | 69.32 Mn | 69.61 Mn | 6.38 Mn | 38.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.49% |
| Dec 31, 2025 | -83.09% |
| Sep 30, 2025 | -212.13% |
| Jun 30, 2025 | -33.38% |
| Mar 31, 2025 | -28.28% |
| Dec 31, 2024 | 796.00% |
| Sep 30, 2024 | 1,018.77% |
| Jun 30, 2024 | -63.66% |
| Mar 31, 2024 | 19.26% |
| Dec 31, 2023 | 89.16% |
| Sep 30, 2023 | 92.71% |
| Jun 30, 2023 | 16.96% |
| Mar 31, 2023 | -152.70% |
| Dec 31, 2022 | -441.01% |
| Sep 30, 2022 | -111.30% |
| Jun 30, 2022 | -88.93% |
| Mar 31, 2022 | 43.95% |
| Dec 31, 2021 | 57.42% |
| Sep 30, 2021 | -3,527.87% |
| Jun 30, 2021 | 73.19% |
| Mar 31, 2021 | 26.81% |
| Dec 31, 2020 | 69.30% |